Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $50 on, Feb 15th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $50 on, Feb 15th, 2023.
Andrew has made no other calls on AMLX in the last 4 months.
There is 1 other peer that has a rating on AMLX. Out of the 1 peers that are also analyzing AMLX, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Geoff Meacham of "B of A Securities" Initiated at Strong Buy and Held Target at $50 on, Thursday, January 5th, 2023
